Oct 2026
Real‐world outcomes in circulating tumor DNA–detected isocitrate dehydrogenase 1–mutant cholangiocarcinoma: First‐line gemcitabine and cisplatin with versus without immunotherapy
This study evaluated outcomes with 1L GemCis versus GemCis + ICI in ctDNA‐identified IDH1‐mutant aCCA in ctDNA‐identified IDH1‐mutant aCCA.
Richard D. Kim, N. Naleid, A. Bubie et al.
· Cancer · 0 citations